NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Bryan J. Schneider(University of Michigan), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center), Stephanie Andrews(Moffitt Cancer Center), Philippe Armand(Dana-Farber Brigham Cancer Center), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lihua E. Budde(City Of Hope National Medical Center), Luciano J. Costa(University of Colorado Cancer Center), Marianne Davies(Smilow Cancer Hospital), David Dunnington(Roswell Park Comprehensive Cancer Center), Marc S. Ernstoff(Otsuka (Japan)), Matthew J. Frigault(Massachusetts General Hospital), Benjamin H. Kaffenberger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Matthew A. Lunning(Otsuka (Japan)), Suzanne McGettigan(University of Pennsylvania), Jordan P. McPherson(University of Utah), Nisha Mohindra(Fox Chase Cancer Center), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Anthony J. Olszanski(Otsuka (Japan)), Olalekan O. Oluwole(Otsuka (Japan)), Sandip Pravin Patel(University of California San Diego), Nathan A. Pennell(Cleveland Clinic), Sunil Reddy(Cancer Institute (WIA)), Mabel Ryder, Bianca Santomasso(Memorial Sloan Kettering Cancer Center), Scott Shofer(Cancer Institute (WIA)), Jeffrey A. Sosman(Fox Chase Cancer Center), Yinghong Wang(The University of Texas MD Anderson Cancer Center), Ryan Weight(University of Colorado Cancer Center), Alyse Johnson-Chilla(Pancreatic Cancer Action Network), Griselda Zuccarino-Catania(Pancreatic Cancer Action Network), Anita M. Engh(Pancreatic Cancer Action Network)
Cited by 483Open Access
Abstract
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.
Related Papers
No related papers found
Powered by citation graph analysis